All In Biotech

Drug Trial Radar · NCT06420440

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

Efficacy and Safety of Neoadjuvant HAIC Combined With Tislelizumab and Lenvatinib in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model: a Multicenter Randomized Controlled Trial.

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jun 1, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Chen XiaopingAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.

Conditions

  • HCC

Interventions

  • Hepatic arterial infusion chemotherapyProcedure

    Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days)

  • LenvatinibDrug

    Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued approximately two weeks before surgery, Oral 8 mg or 12mg once a day depending body weight).

  • TislelizumabDrug

    Patients in the neoadjuvant therapy group received two cycles of Tislelizumab therapy before surgery (First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)

  • Liver resectionProcedure

    Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.

  • TislelizumabDrug

    Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median event-free survival (EFS)Time frame: From date of randomization until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 60 months.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Shanxi Bethune Hospital

    Shanxi, China · Recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • Jingmen Central Hospital

    Jingmen, Hubei, China · Recruiting

  • Shiyan Taihe Hospital

    Shiyan, Hubei, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Shandong Provincial Hospital Affiliated to Shandong First Medical University

    Jinan, Shangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.